PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome
Background: This study focuses on uncovering the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in attenuating arterial stiffness in patients with acute coronary syndrome (ACS) and atherosclerosis. Methods: A total of 71 ACS patients were enrolled in this study from Apri...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Medical Biochemists of Serbia, Belgrade
2025-01-01
|
| Series: | Journal of Medical Biochemistry |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582503412W.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849427933509189632 |
|---|---|
| author | Wang Liang Wang Ruijie Jiao Tiantian Xu Linghao Ji Endong Jiang Yuanzhen Wang Yuanqi Liu Yehong Li Jiming |
| author_facet | Wang Liang Wang Ruijie Jiao Tiantian Xu Linghao Ji Endong Jiang Yuanzhen Wang Yuanqi Liu Yehong Li Jiming |
| author_sort | Wang Liang |
| collection | DOAJ |
| description | Background: This study focuses on uncovering the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in attenuating arterial stiffness in patients with acute coronary syndrome (ACS) and atherosclerosis. Methods: A total of 71 ACS patients were enrolled in this study from April 1, 2022, to June 31, 2022. Patients were randomly assigned to two groups: one group received statin therapy combined with PCSK9 inhibitors (Evolocumab 140 mg or Alirocumab 75 mg every two weeks) (n = 36), and the other group received statins alone (n = 35). All patients underwent measurements of lipid metabolism and arterial stiffness at baseline, 1 month, and 6 months after treatment initiation. Statistical power analysis indicated that the sample size of 71 patients provided sufficient power to detect significant differences. Results: After 1 month, the group treated with statins and PCSK9 inhibitors showed significantly greater reductions in total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and lipoprotein(a) [Lp(a)] levels compared to the statin-only group (p = 0.027 and p = 0.021, respectively). By the 6-month follow-up, significant reductions were observed in pulse wave velocity (PWV) and ankle-brachial index (ABI) in the combination treatment group (p < 0.05). However, no significant differences were observed between Evolocumab and Alirocumab in terms of arterial stiffness improvement (p > 0.05). Statistical power was sufficient to detect these changes. Conclusions: The findings suggest that PCSK9 inhibitors, when combined with statins, not only improve lipid metabolism but also reduce arterial stiffness, offering potential benefits for vascular health in patients with ACS and atherosclerosis. Further studies with larger sample sizes and longer follow-up periods are necessary to confirm these results. |
| format | Article |
| id | doaj-art-c80604bdda094bc798d9d27b50c7582c |
| institution | Kabale University |
| issn | 1452-8258 1452-8266 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Society of Medical Biochemists of Serbia, Belgrade |
| record_format | Article |
| series | Journal of Medical Biochemistry |
| spelling | doaj-art-c80604bdda094bc798d9d27b50c7582c2025-08-20T03:28:51ZengSociety of Medical Biochemists of Serbia, BelgradeJournal of Medical Biochemistry1452-82581452-82662025-01-0144341242110.5937/jomb0-547731452-82582503412WPCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndromeWang Liang0Wang Ruijie1Jiao Tiantian2Xu Linghao3Ji Endong4Jiang Yuanzhen5Wang Yuanqi6Liu Yehong7Li Jiming8Tongji University, School of Medicine, Shanghai East Hospital, Shanghai, ChinaTongji University, School of Medicine, Shanghai East Hospital, Shanghai, ChinaTongji University, School of Medicine, Shanghai East Hospital, Shanghai, ChinaTongji University, School of Medicine, Shanghai East Hospital, Shanghai, ChinaTongji University, School of Medicine, Shanghai East Hospital, Shanghai, ChinaTongji University, School of Medicine, Shanghai East Hospital, Shanghai, ChinaTongji University, School of Medicine, Shanghai East Hospital, Shanghai, ChinaTongji University, School of Medicine, Shanghai East Hospital, Shanghai, ChinaTongji University, School of Medicine, Shanghai East Hospital, Shanghai, ChinaBackground: This study focuses on uncovering the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in attenuating arterial stiffness in patients with acute coronary syndrome (ACS) and atherosclerosis. Methods: A total of 71 ACS patients were enrolled in this study from April 1, 2022, to June 31, 2022. Patients were randomly assigned to two groups: one group received statin therapy combined with PCSK9 inhibitors (Evolocumab 140 mg or Alirocumab 75 mg every two weeks) (n = 36), and the other group received statins alone (n = 35). All patients underwent measurements of lipid metabolism and arterial stiffness at baseline, 1 month, and 6 months after treatment initiation. Statistical power analysis indicated that the sample size of 71 patients provided sufficient power to detect significant differences. Results: After 1 month, the group treated with statins and PCSK9 inhibitors showed significantly greater reductions in total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and lipoprotein(a) [Lp(a)] levels compared to the statin-only group (p = 0.027 and p = 0.021, respectively). By the 6-month follow-up, significant reductions were observed in pulse wave velocity (PWV) and ankle-brachial index (ABI) in the combination treatment group (p < 0.05). However, no significant differences were observed between Evolocumab and Alirocumab in terms of arterial stiffness improvement (p > 0.05). Statistical power was sufficient to detect these changes. Conclusions: The findings suggest that PCSK9 inhibitors, when combined with statins, not only improve lipid metabolism but also reduce arterial stiffness, offering potential benefits for vascular health in patients with ACS and atherosclerosis. Further studies with larger sample sizes and longer follow-up periods are necessary to confirm these results.https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582503412W.pdfpcsk9 inhibitorsacute coronary syndrome (acs)arterial stiffness |
| spellingShingle | Wang Liang Wang Ruijie Jiao Tiantian Xu Linghao Ji Endong Jiang Yuanzhen Wang Yuanqi Liu Yehong Li Jiming PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome Journal of Medical Biochemistry pcsk9 inhibitors acute coronary syndrome (acs) arterial stiffness |
| title | PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome |
| title_full | PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome |
| title_fullStr | PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome |
| title_full_unstemmed | PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome |
| title_short | PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome |
| title_sort | pcsk9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome |
| topic | pcsk9 inhibitors acute coronary syndrome (acs) arterial stiffness |
| url | https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582503412W.pdf |
| work_keys_str_mv | AT wangliang pcsk9inhibitorsreducesarterialstiffnessinpatientswithacutecoronarysyndrome AT wangruijie pcsk9inhibitorsreducesarterialstiffnessinpatientswithacutecoronarysyndrome AT jiaotiantian pcsk9inhibitorsreducesarterialstiffnessinpatientswithacutecoronarysyndrome AT xulinghao pcsk9inhibitorsreducesarterialstiffnessinpatientswithacutecoronarysyndrome AT jiendong pcsk9inhibitorsreducesarterialstiffnessinpatientswithacutecoronarysyndrome AT jiangyuanzhen pcsk9inhibitorsreducesarterialstiffnessinpatientswithacutecoronarysyndrome AT wangyuanqi pcsk9inhibitorsreducesarterialstiffnessinpatientswithacutecoronarysyndrome AT liuyehong pcsk9inhibitorsreducesarterialstiffnessinpatientswithacutecoronarysyndrome AT lijiming pcsk9inhibitorsreducesarterialstiffnessinpatientswithacutecoronarysyndrome |